COVID-19 Antibody Therapeutics Tracker

COVID-19 Antibody Therapeutics Tracker tracks and curates antibody therapeutics for prevention and treatment of COVID-19 by aggregating annotated data on targets, therapeutic formats, development stages, developers, and countries to support analysis of SARS-CoV-2 antibody development.

Key Features:

• Curated aggregation: Aggregates and curates entries from public sources with continuous verification by a network of volunteers.
• Scope and content: Contains information on over 150 research and development programs and molecules involved in antibody-based interventions against SARS-CoV-2 (as of August 8, 2020).
• Categorization: Classifies entries by target antigens, therapeutic formats, current stage of development, developers, and country of origin.
• Target emphasis: Highlights antibodies targeting the SARS-CoV-2 spike protein (S protein) and reports that the majority are full-length monoclonal antibodies.
• Documented candidates: Documents clinical-stage candidates including LY-CoV555, REGN-COV2, JS016, TY027, CT-P59, BRII-196, BRII-198, and SCTA01.
• Trend tracking: Tracks repurposed non-virus-specific antibody therapeutics and virus-specific antibodies progressing through discovery, preclinical, and clinical phases.
• Data visualization: Provides visualization of aggregated data to aid analysis of development trends.

Scientific Applications:

• Landscape monitoring: Enables monitoring of the global antibody therapeutic development landscape for prevention and treatment of COVID-19.
• Target and format analysis: Supports analysis of antigen targets and therapeutic formats, including emphasis on spike protein-targeting and full-length monoclonal antibodies.
• Clinical candidate comparison: Facilitates identification and comparison of clinical-stage neutralizing antibodies to support clinical evaluation and prioritization.
• Repurposing assessment: Enables tracking of repurposed versus virus-specific antibody candidates across development stages.

Methodology:

Aggregates data from public sources with continuous volunteer verification, categorizes entries by antigen targets, therapeutic format, development stage, developers, and country of origin, and generates visualizations of the aggregated data.